Front Matter
Article Sidebar
Main Article Content
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.
Waldemar Debinski, MD, PhD (ed), Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston Salem, NC, USA
Waldemar Debinski, MD, PhD, is Tom and Laura Hearn Professor for the Brain Tumor Center of Excellence (BTCOE), Director of the BTCOE and Leader of the Neuro-Oncology Program at Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, North Carolina, USA. He graduated from Warsaw Academy of Medicine (Warsaw, Poland) and McGill University (Montreal, Canada) with MD and PhD degrees, respectively. He did a post- PhD training at the National Cancer Institute (Bethesda, MD, USA). Dr. Debinski is the author or co-author of >160 peer reviewed publications and an inventor on 27 patents. He has been primarily interested in potential clinical applications of medical research and thus in its translational side. Dr. Debinski has extensive experience in successful discovery of targets specific to cancer, their pathophysiological role in cancer, and rational engineering of targeted recombinant proteins including chimera and conjugated proteins, and peptides. He has a particular interest in loco-regional delivery of drugs to brain tumors and in faithful large animal models of the disease. His work has been a substrate for numerous translational applications, many being tested in the clinic. Dr. Debinski’s research has been continuously supported by federal, provincial, institutional, or private funding sources for the past 25 years.